Avanir To Present Data From Studies For Alzheimer's With Agitation, PBA Effect

(RTTNews) - Avanir Pharmaceuticals, Inc. (AVNR) Wednesday said it will present data from a Phase 2 trial on treatment of agitation in patients with Alzheimer's, and from a Phase 4 trial on treatment of pseudobulbar affect in Alzheimer's patients, at the American Neurological Association's meeting in Baltimore.

The study for agitation in patients with Alzheimer's was a 10-week, randomized, double-blind study, with the the agitation/aggression subscale of the Neuropsychiatric Inventory being the main efficacy measure.

The Phase 4 trial, named Prism 2, tested the effect of Nuedexta capsules containing 20 mg dextromethorphan and 10 mg quinidine on PBA in patients with prevalent neurological conditions including Alzheimer's disease/dementia, stroke and traumatic brain injury.

The primary endpoint of Prism 2 is the change from baseline in Center for Neurologic Study-Lability Scale.

The company will present the data at 5:30 pm to 7:00 pm on Monday, October 13.